Fractyl Health (NASDAQ:GUTS – Get Free Report) and LivaNova (NASDAQ:LIVN – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability.
Earnings and Valuation
This table compares Fractyl Health and LivaNova”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fractyl Health | $90,000.00 | 143.87 | -$140.95 million | ($10.56) | -0.09 |
| LivaNova | $1.39 billion | 3.13 | -$242.47 million | $3.38 | 23.36 |
Fractyl Health has higher earnings, but lower revenue than LivaNova. Fractyl Health is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Fractyl Health has a beta of 2.42, meaning that its stock price is 142% more volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings for Fractyl Health and LivaNova, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fractyl Health | 1 | 1 | 3 | 0 | 2.40 |
| LivaNova | 0 | 3 | 7 | 1 | 2.82 |
Fractyl Health currently has a consensus price target of $50.25, suggesting a potential upside of 5,045.93%. LivaNova has a consensus price target of $87.75, suggesting a potential upside of 11.12%. Given Fractyl Health’s higher probable upside, research analysts plainly believe Fractyl Health is more favorable than LivaNova.
Insider & Institutional Ownership
97.6% of LivaNova shares are held by institutional investors. 8.4% of Fractyl Health shares are held by company insiders. Comparatively, 0.3% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Fractyl Health and LivaNova’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fractyl Health | N/A | -1,362.10% | -84.89% |
| LivaNova | 12.82% | 16.35% | 7.76% |
Summary
LivaNova beats Fractyl Health on 9 of the 14 factors compared between the two stocks.
About Fractyl Health
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
About LivaNova
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
Receive News & Ratings for Fractyl Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fractyl Health and related companies with MarketBeat.com's FREE daily email newsletter.
